Abstract
When [3H]benzo[a]pyrene is incubated in vitro together with deproteinized salmon sperm DNA, NADPH, and mouse liver microsomes, the covalent binding of benzo[a]pyrene metabolites to DNA occurs. The metabolite-nucleoside complexes can be resolved into at least nine distinct peaks by elution of a Sephadex LH-20 column with a water-methanol gradient. These peaks are arbitrarily designated A (most polar) through I (least polar). With the use of synthetic and biologically produced metabolites, seven of nine peaks are tentatively assigned to one or more metabolites of benzo[a]pyrene. Peaks A and C are unidentified. Peaks B, D, F, and I include products of benzo[a]pyrene quinones that are further metabolized. Peak E reflects almost exclusively both the cis- and trans-7,8-diol 9,10-epoxides of benzo[a]pyrene. Peak G represents predominantly the K-region metabolite (the 4,5-oxide), interacting with one or more nucleosides. Peak H comprises reactive intermediates resulting from the further metabolism of benzo[a]pyrene phenols. The 7,8-oxide and the 9,10-oxide contribute to peaks E, F, G, and H. Benzo[a] pyrene thus may be metabolized to four different "types" of reactive intermediates capable of binding to DNA: (a) primary arene oxides, (b) diol epoxides, (c) phenols oxygenated further, and (d) quinones oxygenated further (or quinone-derived free radicals). These last three types of microsomally activated intermediates are therefore the result of two- or three-step enzymatic processes in which cytochrome P-450-mediated monooxygenations occur at least twice.
ACKNOWLEDGMENT We appreciate the expert secretarial assistance of Ms. Ingrid E. Jordan.
- Copyright © 1978 by Academic Press, Inc.
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|